Table of Content

1 Myasthenia Gravis Treatment Market Overview
1.1 Product Overview and Scope of Myasthenia Gravis Treatment
1.2 Myasthenia Gravis Treatment Segment by Type
1.2.1 Global Myasthenia Gravis Treatment Market Value Comparison by Type (2024-2034)
1.2.2 Monoclonal Antibodies
1.2.3 Intravenous Immunoglobulin
1.2.4 Other
1.3 Myasthenia Gravis Treatment Segment by Application
1.3.1 Global Myasthenia Gravis Treatment Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Other
1.4 Global Myasthenia Gravis Treatment Market Size Estimates and Forecasts
1.4.1 Global Myasthenia Gravis Treatment Revenue 2018-2029
1.4.2 Global Myasthenia Gravis Treatment Sales 2018-2029
1.4.3 Global Myasthenia Gravis Treatment Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Myasthenia Gravis Treatment Market Competition by Manufacturers
2.1 Global Myasthenia Gravis Treatment Sales Market Share by Manufacturers (2018-2024)
2.2 Global Myasthenia Gravis Treatment Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Myasthenia Gravis Treatment Average Price by Manufacturers (2018-2024)
2.4 Global Myasthenia Gravis Treatment Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Myasthenia Gravis Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Myasthenia Gravis Treatment, Product Type & Application
2.7 Myasthenia Gravis Treatment Market Competitive Situation and Trends
2.7.1 Myasthenia Gravis Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Myasthenia Gravis Treatment Players Market Share by Revenue
2.7.3 Global Myasthenia Gravis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Myasthenia Gravis Treatment Retrospective Market Scenario by Region
3.1 Global Myasthenia Gravis Treatment Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Myasthenia Gravis Treatment Global Myasthenia Gravis Treatment Sales by Region: 2018-2029
3.2.1 Global Myasthenia Gravis Treatment Sales by Region: 2018-2024
3.2.2 Global Myasthenia Gravis Treatment Sales by Region: 2024-2029
3.3 Global Myasthenia Gravis Treatment Global Myasthenia Gravis Treatment Revenue by Region: 2018-2029
3.3.1 Global Myasthenia Gravis Treatment Revenue by Region: 2018-2024
3.3.2 Global Myasthenia Gravis Treatment Revenue by Region: 2024-2029
3.4 North America Myasthenia Gravis Treatment Market Facts & Figures by Country
3.4.1 North America Myasthenia Gravis Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Myasthenia Gravis Treatment Sales by Country (2018-2029)
3.4.3 North America Myasthenia Gravis Treatment Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Myasthenia Gravis Treatment Market Facts & Figures by Country
3.5.1 Europe Myasthenia Gravis Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Myasthenia Gravis Treatment Sales by Country (2018-2029)
3.5.3 Europe Myasthenia Gravis Treatment Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Myasthenia Gravis Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Myasthenia Gravis Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Myasthenia Gravis Treatment Sales by Country (2018-2029)
3.6.3 Asia Pacific Myasthenia Gravis Treatment Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Myasthenia Gravis Treatment Market Facts & Figures by Country
3.7.1 Latin America Myasthenia Gravis Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Myasthenia Gravis Treatment Sales by Country (2018-2029)
3.7.3 Latin America Myasthenia Gravis Treatment Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Myasthenia Gravis Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Myasthenia Gravis Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2018-2029)
3.8.3 Middle East and Africa Myasthenia Gravis Treatment Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Myasthenia Gravis Treatment Sales by Type (2018-2029)
4.1.1 Global Myasthenia Gravis Treatment Sales by Type (2018-2024)
4.1.2 Global Myasthenia Gravis Treatment Sales by Type (2024-2029)
4.1.3 Global Myasthenia Gravis Treatment Sales Market Share by Type (2018-2029)
4.2 Global Myasthenia Gravis Treatment Revenue by Type (2018-2029)
4.2.1 Global Myasthenia Gravis Treatment Revenue by Type (2018-2024)
4.2.2 Global Myasthenia Gravis Treatment Revenue by Type (2024-2029)
4.2.3 Global Myasthenia Gravis Treatment Revenue Market Share by Type (2018-2029)
4.3 Global Myasthenia Gravis Treatment Price by Type (2018-2029)
5 Segment by Application
5.1 Global Myasthenia Gravis Treatment Sales by Application (2018-2029)
5.1.1 Global Myasthenia Gravis Treatment Sales by Application (2018-2024)
5.1.2 Global Myasthenia Gravis Treatment Sales by Application (2024-2029)
5.1.3 Global Myasthenia Gravis Treatment Sales Market Share by Application (2018-2029)
5.2 Global Myasthenia Gravis Treatment Revenue by Application (2018-2029)
5.2.1 Global Myasthenia Gravis Treatment Revenue by Application (2018-2024)
5.2.2 Global Myasthenia Gravis Treatment Revenue by Application (2024-2029)
5.2.3 Global Myasthenia Gravis Treatment Revenue Market Share by Application (2018-2029)
5.3 Global Myasthenia Gravis Treatment Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Amneal Pharmaceuticals, Inc.
6.1.1 Amneal Pharmaceuticals, Inc. Corporation Information
6.1.2 Amneal Pharmaceuticals, Inc. Description and Business Overview
6.1.3 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product Portfolio
6.1.5 Amneal Pharmaceuticals, Inc. Recent Developments/Updates
6.2 Astellas Pharma, Inc.
6.2.1 Astellas Pharma, Inc. Corporation Information
6.2.2 Astellas Pharma, Inc. Description and Business Overview
6.2.3 Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Astellas Pharma, Inc. Myasthenia Gravis Treatment Product Portfolio
6.2.5 Astellas Pharma, Inc. Recent Developments/Updates
6.3 Avadel Pharmaceuticals PLC
6.3.1 Avadel Pharmaceuticals PLC Corporation Information
6.3.2 Avadel Pharmaceuticals PLC Description and Business Overview
6.3.3 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product Portfolio
6.3.5 Avadel Pharmaceuticals PLC Recent Developments/Updates
6.4 Bausch Health Companies Inc.
6.4.1 Bausch Health Companies Inc. Corporation Information
6.4.2 Bausch Health Companies Inc. Description and Business Overview
6.4.3 Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Bausch Health Companies Inc. Myasthenia Gravis Treatment Product Portfolio
6.4.5 Bausch Health Companies Inc. Recent Developments/Updates
6.5 CSL Behring
6.5.1 CSL Behring Corporation Information
6.5.2 CSL Behring Description and Business Overview
6.5.3 CSL Behring Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.5.4 CSL Behring Myasthenia Gravis Treatment Product Portfolio
6.5.5 CSL Behring Recent Developments/Updates
6.6 CuraVac, Inc.
6.6.1 CuraVac, Inc. Corporation Information
6.6.2 CuraVac, Inc. Description and Business Overview
6.6.3 CuraVac, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.6.4 CuraVac, Inc. Myasthenia Gravis Treatment Product Portfolio
6.6.5 CuraVac, Inc. Recent Developments/Updates
6.7 Argenx SE
6.6.1 Argenx SE Corporation Information
6.6.2 Argenx SE Description and Business Overview
6.6.3 Argenx SE Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Argenx SE Myasthenia Gravis Treatment Product Portfolio
6.7.5 Argenx SE Recent Developments/Updates
6.8 GlaxoSmithKline plc
6.8.1 GlaxoSmithKline plc Corporation Information
6.8.2 GlaxoSmithKline plc Description and Business Overview
6.8.3 GlaxoSmithKline plc Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.8.4 GlaxoSmithKline plc Myasthenia Gravis Treatment Product Portfolio
6.8.5 GlaxoSmithKline plc Recent Developments/Updates
6.9 Immunovant, Inc.
6.9.1 Immunovant, Inc. Corporation Information
6.9.2 Immunovant, Inc. Description and Business Overview
6.9.3 Immunovant, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Immunovant, Inc. Myasthenia Gravis Treatment Product Portfolio
6.9.5 Immunovant, Inc. Recent Developments/Updates
6.10 Mitsubishi Tanabe Pharma Corp.
6.10.1 Mitsubishi Tanabe Pharma Corp. Corporation Information
6.10.2 Mitsubishi Tanabe Pharma Corp. Description and Business Overview
6.10.3 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product Portfolio
6.10.5 Mitsubishi Tanabe Pharma Corp. Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Corporation Information
6.11.2 Novartis AG Myasthenia Gravis Treatment Description and Business Overview
6.11.3 Novartis AG Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Novartis AG Myasthenia Gravis Treatment Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 Takeda Pharmaceutical Co., Ltd.
6.12.1 Takeda Pharmaceutical Co., Ltd. Corporation Information
6.12.2 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Description and Business Overview
6.12.3 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product Portfolio
6.12.5 Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates
6.13 UCB Pharma
6.13.1 UCB Pharma Corporation Information
6.13.2 UCB Pharma Myasthenia Gravis Treatment Description and Business Overview
6.13.3 UCB Pharma Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.13.4 UCB Pharma Myasthenia Gravis Treatment Product Portfolio
6.13.5 UCB Pharma Recent Developments/Updates
6.14 AstraZeneca
6.14.1 AstraZeneca Corporation Information
6.14.2 AstraZeneca Myasthenia Gravis Treatment Description and Business Overview
6.14.3 AstraZeneca Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.14.4 AstraZeneca Myasthenia Gravis Treatment Product Portfolio
6.14.5 AstraZeneca Recent Developments/Updates
6.15 F. Hoffmann-La Roche Ltd
6.15.1 F. Hoffmann-La Roche Ltd Corporation Information
6.15.2 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Description and Business Overview
6.15.3 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2018-2024)
6.15.4 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Product Portfolio
6.15.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Myasthenia Gravis Treatment Industry Chain Analysis
7.2 Myasthenia Gravis Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Myasthenia Gravis Treatment Production Mode & Process
7.4 Myasthenia Gravis Treatment Sales and Marketing
7.4.1 Myasthenia Gravis Treatment Sales Channels
7.4.2 Myasthenia Gravis Treatment Distributors
7.5 Myasthenia Gravis Treatment Customers
8 Myasthenia Gravis Treatment Market Dynamics
8.1 Myasthenia Gravis Treatment Industry Trends
8.2 Myasthenia Gravis Treatment Market Drivers
8.3 Myasthenia Gravis Treatment Market Challenges
8.4 Myasthenia Gravis Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Myasthenia Gravis Treatment Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Myasthenia Gravis Treatment Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Myasthenia Gravis Treatment Market Competitive Situation by Manufacturers in 2022
Table 4. Global Myasthenia Gravis Treatment Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Myasthenia Gravis Treatment Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Myasthenia Gravis Treatment Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Myasthenia Gravis Treatment Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Myasthenia Gravis Treatment, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Myasthenia Gravis Treatment, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Myasthenia Gravis Treatment, Product Type & Application
Table 12. Global Key Manufacturers of Myasthenia Gravis Treatment, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Myasthenia Gravis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis Treatment as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Myasthenia Gravis Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Myasthenia Gravis Treatment Sales by Region (2018-2024) & (K Units)
Table 18. Global Myasthenia Gravis Treatment Sales Market Share by Region (2018-2024)
Table 19. Global Myasthenia Gravis Treatment Sales by Region (2024-2029) & (K Units)
Table 20. Global Myasthenia Gravis Treatment Sales Market Share by Region (2024-2029)
Table 21. Global Myasthenia Gravis Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Myasthenia Gravis Treatment Revenue Market Share by Region (2018-2024)
Table 23. Global Myasthenia Gravis Treatment Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Myasthenia Gravis Treatment Revenue Market Share by Region (2024-2029)
Table 25. North America Myasthenia Gravis Treatment Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 27. North America Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 28. North America Myasthenia Gravis Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Myasthenia Gravis Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Myasthenia Gravis Treatment Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 32. Europe Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 33. Europe Myasthenia Gravis Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Myasthenia Gravis Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Myasthenia Gravis Treatment Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Myasthenia Gravis Treatment Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Myasthenia Gravis Treatment Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Myasthenia Gravis Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Myasthenia Gravis Treatment Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Myasthenia Gravis Treatment Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Myasthenia Gravis Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Myasthenia Gravis Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Myasthenia Gravis Treatment Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Myasthenia Gravis Treatment Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Myasthenia Gravis Treatment Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Myasthenia Gravis Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Myasthenia Gravis Treatment Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Myasthenia Gravis Treatment Sales (K Units) by Type (2018-2024)
Table 51. Global Myasthenia Gravis Treatment Sales (K Units) by Type (2024-2029)
Table 52. Global Myasthenia Gravis Treatment Sales Market Share by Type (2018-2024)
Table 53. Global Myasthenia Gravis Treatment Sales Market Share by Type (2024-2029)
Table 54. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Myasthenia Gravis Treatment Revenue Market Share by Type (2018-2024)
Table 57. Global Myasthenia Gravis Treatment Revenue Market Share by Type (2024-2029)
Table 58. Global Myasthenia Gravis Treatment Price (US$/Unit) by Type (2018-2024)
Table 59. Global Myasthenia Gravis Treatment Price (US$/Unit) by Type (2024-2029)
Table 60. Global Myasthenia Gravis Treatment Sales (K Units) by Application (2018-2024)
Table 61. Global Myasthenia Gravis Treatment Sales (K Units) by Application (2024-2029)
Table 62. Global Myasthenia Gravis Treatment Sales Market Share by Application (2018-2024)
Table 63. Global Myasthenia Gravis Treatment Sales Market Share by Application (2024-2029)
Table 64. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Myasthenia Gravis Treatment Revenue Market Share by Application (2018-2024)
Table 67. Global Myasthenia Gravis Treatment Revenue Market Share by Application (2024-2029)
Table 68. Global Myasthenia Gravis Treatment Price (US$/Unit) by Application (2018-2024)
Table 69. Global Myasthenia Gravis Treatment Price (US$/Unit) by Application (2024-2029)
Table 70. Amneal Pharmaceuticals, Inc. Corporation Information
Table 71. Amneal Pharmaceuticals, Inc. Description and Business Overview
Table 72. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product
Table 74. Amneal Pharmaceuticals, Inc. Recent Developments/Updates
Table 75. Astellas Pharma, Inc. Corporation Information
Table 76. Astellas Pharma, Inc. Description and Business Overview
Table 77. Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Astellas Pharma, Inc. Myasthenia Gravis Treatment Product
Table 79. Astellas Pharma, Inc. Recent Developments/Updates
Table 80. Avadel Pharmaceuticals PLC Corporation Information
Table 81. Avadel Pharmaceuticals PLC Description and Business Overview
Table 82. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product
Table 84. Avadel Pharmaceuticals PLC Recent Developments/Updates
Table 85. Bausch Health Companies Inc. Corporation Information
Table 86. Bausch Health Companies Inc. Description and Business Overview
Table 87. Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Bausch Health Companies Inc. Myasthenia Gravis Treatment Product
Table 89. Bausch Health Companies Inc. Recent Developments/Updates
Table 90. CSL Behring Corporation Information
Table 91. CSL Behring Description and Business Overview
Table 92. CSL Behring Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. CSL Behring Myasthenia Gravis Treatment Product
Table 94. CSL Behring Recent Developments/Updates
Table 95. CuraVac, Inc. Corporation Information
Table 96. CuraVac, Inc. Description and Business Overview
Table 97. CuraVac, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. CuraVac, Inc. Myasthenia Gravis Treatment Product
Table 99. CuraVac, Inc. Recent Developments/Updates
Table 100. Argenx SE Corporation Information
Table 101. Argenx SE Description and Business Overview
Table 102. Argenx SE Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Argenx SE Myasthenia Gravis Treatment Product
Table 104. Argenx SE Recent Developments/Updates
Table 105. GlaxoSmithKline plc Corporation Information
Table 106. GlaxoSmithKline plc Description and Business Overview
Table 107. GlaxoSmithKline plc Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. GlaxoSmithKline plc Myasthenia Gravis Treatment Product
Table 109. GlaxoSmithKline plc Recent Developments/Updates
Table 110. Immunovant, Inc. Corporation Information
Table 111. Immunovant, Inc. Description and Business Overview
Table 112. Immunovant, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Immunovant, Inc. Myasthenia Gravis Treatment Product
Table 114. Immunovant, Inc. Recent Developments/Updates
Table 115. Mitsubishi Tanabe Pharma Corp. Corporation Information
Table 116. Mitsubishi Tanabe Pharma Corp. Description and Business Overview
Table 117. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product
Table 119. Mitsubishi Tanabe Pharma Corp. Recent Developments/Updates
Table 120. Novartis AG Corporation Information
Table 121. Novartis AG Description and Business Overview
Table 122. Novartis AG Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Novartis AG Myasthenia Gravis Treatment Product
Table 124. Novartis AG Recent Developments/Updates
Table 125. Takeda Pharmaceutical Co., Ltd. Corporation Information
Table 126. Takeda Pharmaceutical Co., Ltd. Description and Business Overview
Table 127. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product
Table 129. Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 130. UCB Pharma Corporation Information
Table 131. UCB Pharma Description and Business Overview
Table 132. UCB Pharma Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. UCB Pharma Myasthenia Gravis Treatment Product
Table 134. UCB Pharma Recent Developments/Updates
Table 135. AstraZeneca Corporation Information
Table 136. AstraZeneca Description and Business Overview
Table 137. AstraZeneca Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. AstraZeneca Myasthenia Gravis Treatment Product
Table 139. AstraZeneca Recent Developments/Updates
Table 140. F. Hoffmann-La Roche Ltd Corporation Information
Table 141. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 142. F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Product
Table 144. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Myasthenia Gravis Treatment Distributors List
Table 148. Myasthenia Gravis Treatment Customers List
Table 149. Myasthenia Gravis Treatment Market Trends
Table 150. Myasthenia Gravis Treatment Market Drivers
Table 151. Myasthenia Gravis Treatment Market Challenges
Table 152. Myasthenia Gravis Treatment Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Myasthenia Gravis Treatment
Figure 2. Global Myasthenia Gravis Treatment Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Myasthenia Gravis Treatment Market Share by Type in 2022 & 2029
Figure 4. Monoclonal Antibodies Product Picture
Figure 5. Intravenous Immunoglobulin Product Picture
Figure 6. Other Product Picture
Figure 7. Global Myasthenia Gravis Treatment Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Myasthenia Gravis Treatment Market Share by Application in 2022 & 2029
Figure 9. Hospital
Figure 10. Specialist Clinic
Figure 11. Other
Figure 12. Global Myasthenia Gravis Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Myasthenia Gravis Treatment Market Size (2018-2029) & (US$ Million)
Figure 14. Global Myasthenia Gravis Treatment Sales (2018-2029) & (K Units)
Figure 15. Global Myasthenia Gravis Treatment Average Price (US$/Unit) & (2018-2029)
Figure 16. Myasthenia Gravis Treatment Report Years Considered
Figure 17. Myasthenia Gravis Treatment Sales Share by Manufacturers in 2022
Figure 18. Global Myasthenia Gravis Treatment Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Myasthenia Gravis Treatment Players: Market Share by Revenue in 2022
Figure 20. Myasthenia Gravis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Myasthenia Gravis Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Myasthenia Gravis Treatment Sales Market Share by Country (2018-2029)
Figure 23. North America Myasthenia Gravis Treatment Revenue Market Share by Country (2018-2029)
Figure 24. United States Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Myasthenia Gravis Treatment Sales Market Share by Country (2018-2029)
Figure 27. Europe Myasthenia Gravis Treatment Revenue Market Share by Country (2018-2029)
Figure 28. Germany Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Myasthenia Gravis Treatment Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Myasthenia Gravis Treatment Revenue Market Share by Region (2018-2029)
Figure 35. China Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Myasthenia Gravis Treatment Sales Market Share by Country (2018-2029)
Figure 45. Latin America Myasthenia Gravis Treatment Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Myasthenia Gravis Treatment Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Myasthenia Gravis Treatment Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Myasthenia Gravis Treatment Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Myasthenia Gravis Treatment by Type (2018-2029)
Figure 55. Global Revenue Market Share of Myasthenia Gravis Treatment by Type (2018-2029)
Figure 56. Global Myasthenia Gravis Treatment Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Myasthenia Gravis Treatment by Application (2018-2029)
Figure 58. Global Revenue Market Share of Myasthenia Gravis Treatment by Application (2018-2029)
Figure 59. Global Myasthenia Gravis Treatment Price (US$/Unit) by Application (2018-2029)
Figure 60. Myasthenia Gravis Treatment Value Chain
Figure 61. Myasthenia Gravis Treatment Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed